0001628280-25-047169
SEC filingQ3 revenue grew 8% to $223M, driven by Nuclear & Safety and Medical; net income turned positive to $3.1M.
For Q3 2025, Mirion reported revenue of $223.1M, up 7.9% from $206.8M in Q3 2024. Gross profit rose 12.5% to $104.5M, with gross margin expanding 190 bps to 46.8%, driven by favorable mix and price increases. Operating income swung to $7.4M from a loss of $1.6M, reflecting revenue growth and lower amortization. Net income was $3.1M versus a loss of $14.0M, aided by a $6.0M reduction in interest expense (from debt refinancing) and a $1.9M income tax benefit. Nine-month results mirrored the trend: revenue +6.8% to $648.0M, net income $12.0M vs loss $52.5M, with benefits from lower interest, foreign currency gains ($16.9M), and absence of warrant liability charges.
Medical segment revenue grew 5.9% in Q3 to $78.5M, driven by organic volume, price increases, and Fx. Operating income surged to $10.7M (13.6% margin) from $4.0M (5.4% margin) due to revenue growth, lower amortization ($1.6M reduction), and reduced restructuring costs. Nuclear & Safety revenue increased 9.0% to $144.6M, with growth from Fx ($3.9M), organic volume ($3.2M), price ($2.5M), and acquisitions ($2.3M). Segment operating income rose to $21.3M (14.7% margin) from $14.7M (11.1% margin), aided by lower amortization and incentive compensation. Corporate costs increased to $24.6M (vs $20.3M) due to M&A expenses and compensation, partially offsetting segment gains.
Management highlighted key growth drivers: nuclear end-market trends (data center demand, clean energy acceptance), medical RT QA expansion, and strategic acquisitions. Recent deals include Certrec (closed July 2025, $82.2M purchase price) and the planned Paragon Energy acquisition (~$585M) expected to close year-end 2025, funded by equity and convertible note offerings. The company's backlog remained stable at $808M, providing revenue visibility. No formal quantitative guidance was provided, but the MD&A emphasizes long-term growth through nuclear new build, digital ecosystem expansion, and leveraging installed base. Risks include geopolitical tensions, sanctions (Russia exposure of $107.3M in backlog), inflation, and interest rate sensitivity. The company expects the 'One Big Beautiful Bill Act' to favorably impact its effective tax rate.
Cash and cash equivalents rose sharply to $933.2M from $175.2M at year-end 2024, primarily from the May and September 2025 convertible note issuances ($400M and $375M) and a $425M common stock offering. The company also holds $6.5M in short-term marketable securities. Total debt increased to $1,198.4M (including $753.6M net convertible debt), while shareholders' equity grew to $1,892.0M. The current ratio (current assets $1,386.6M / current liabilities $287.0M) is a strong 4.8x.
Unconditional purchase obligations total $77.7M as of September 30, 2025, with $45.4M payable in the remainder of 2025, $28.0M in 2026, $2.1M in 2027, $1.8M in 2028, and $0.4M thereafter. Additionally, the company has $808.0M in remaining performance obligations, of which 26% is expected to be recognized in 2025, 35% in 2026, and the rest thereafter.
During the nine months, the company repurchased $49.6M of its Class A common stock (2.94M shares), including $31.0M concurrent with the 2030 Notes offering. No dividends were paid. Debt activity was significant: $775M in convertible notes were issued ($400M 0.25% due 2030, $375M 0.00% due 2031), while $244.6M of the term loan was repaid, resulting in a $5.8M loss on debt extinguishment. Capital expenditures totaled $29.3M (4.5% of sales), with $14.0M in Medical and $13.3M in Nuclear & Safety.
For the nine months ended September 30, 2025, Medical segment revenue was $228.3M (up 6.6% YoY) with operating income of $28.3M (12.4% margin). Nuclear & Safety revenue was $419.7M (up 6.9%) with operating income of $62.0M (14.8% margin). Geographically, North America contributed $413.9M (63.9% of total), Europe $222.9M (34.4%), and Asia Pacific $11.2M. The Nuclear segment saw strong nuclear power plant product demand ($248.1M vs $218.8M in 2024), while Medical cancer care products grew to $173.1M from $162.1M.
The provided document excerpt does not include the actual cash flow statement. Only the header and subsequent notes are listed. Without the numerical data for operating, investing, and financing cash flows, no analysis of cash generation, capex, or capital returns is possible. The balance sheet shows a large increase in cash from $175.2M to $933.2M, but the drivers cannot be determined from the given text.